| 查看: 3802 | 回复: 17 | |||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
中文投稿“肿瘤免疫”相关
已经有6人回复
-
博导推荐
已经有2人回复
-
药理学论文润色/翻译怎么收费?
已经有61人回复
-
哪里做甘氨酸受体与配体结合率的试验
已经有0人回复
-
2025年药学专业求调剂
已经有1人回复
-
参比制剂，自己做的PK数据与IF资料报道的数据相差很大
已经有2人回复
-
祈求中本子
已经有0人回复
-
各位大佬，H口面上什么时候会评？？？
已经有30人回复
-
关于SCI杂志发表挂名
已经有32人回复
-
2026年山东大学海洋学院生物与医药博士招生-李霞课题组
已经有0人回复
-
博士研究生招生
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
散金
+5/965
-
求一个访问学者邀请函，非常非常感谢
+1/680
-
武汉纺织大学电子与电气工程学院------院长团队招聘光电、材料类博士，博士后
+1/486
-
中国科学院大学纳米科学与工程学院唐智勇（院长）-张银团队招聘启事
+1/169
-
美国密歇根州立大学林学系杜海顺课题组招收全奖博士生及联合培养博士生
+1/76
-
希望你在这里
+1/63
-
昆明理工大学冶能院离子液体冶金课题组招收博士
+1/58
-
考核制博士自荐
+1/40
-
厦门大学航空航天学院智能制造课题组招2026年申请审核制博士生1-2名
+1/31
-
北京林业大学木质素高值化利用创新团队招收2026年入学博士生
+1/27
-
香港科技大学 Abhishek Kumar Srivastava 教授课题组 招收博士生
+2/22
-
杨老师招收联合培养硕士、博士生或客座学生
+1/19
-
2026 博士自荐-机器人机构学方向
+1/8
-
【博士后/科研助理招聘-北京理工大学-集成电路与电子学院-国家杰青团队】
+1/7
-
浙江大学傅杰团队(杰青)高薪招聘博士后
+1/5
-
深容SCI智能体四大模块：Method, Introduction, Discussion, Abstract
+1/3
-
电子科技大学激光与光子制造团队招硕士博士
+1/3
-
东方理工朱宸招聘上海交大或中科大联培博士生、博士后（有机合成、DFT、AI自动化）
+1/3
-
吉林大学闫旭教授（国家级青年人才）招收2026级博士研究生
+1/3
-
文献问题求助
+1/1
18楼2013-09-10 18:04:01
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35